
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
[ Tue, May 31st 2022 ]: WOPRAI
Oren Livnat Maintained (VRCA) at Strong Buy with Decreased Target to $12 on, May 31st, 2022


🞛 This publication is a summary or evaluation of another publication
Oren Livnat of HC Wainwright & Co., Maintained "Verrica Pharmaceuticals Inc." (VRCA) at Strong Buy with Decreased Target from $20 to $12 on, May 31st, 2022.
Oren has made no other calls on VRCA in the last 4 months.
There are 3 other peers that have a rating on VRCA. Out of the 3 peers that are also analyzing VRCA, 1 agrees with Oren's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Daniel Busby of "RBC Capital" Downgraded from Buy to Hold and Decreased Target to $4 on, Wednesday, May 25th, 2022
These are the ratings of the 2 analyists that currently disagree with Oren
- Kemp Dolliver of "Brookline Capital" Initiated at Strong Buy and Held Target at $20 on, Thursday, March 10th, 2022
- Serge Belanger of "Needham" Maintained at Strong Buy with Decreased Target to $18 on, Thursday, March 3rd, 2022